Andrew J. Holman, MD, is the CEO and Co-founder of Inmedix, Inc., a private Seattle medtech/biotech defining immuno-autonomics as a new way to manage autoimmune diseases and cancer. He has lectured at clinical symposia worldwide, and also at the Brigham & Women’s Hospital (Harvard), the Hospital for Special Surgery (NYC), the Cleveland Clinic and Guy’s Hospital, London. He completed his undergraduate studies in chemistry at Bowdoin College, his medical degree at the University of Missouri-Columbia and fellowship training at the University of Washington.

He is a Clinical Associate Professor of Medicine at the University of Washington and a former President of the Northwest Rheumatism Society. Before founding Inmedix, he enjoyed a 25-year clinical and 19-year rheumatology research career with 16 lead author peer-reviewed papers and 25 lead author abstracts. For Inmedix, he has designed, completed, and published 15 clinical studies, including FDA negotiations, involving nearly 1500 patients.

His research highlights include broadening the understanding of widespread pain in patients with cervical spine arthritis using flexion-extension cervical magnetic resonance imaging (MRI) and the discovery of dopamine agonists as a treatment for fibromyalgia (FM), leading to a $10M patent portfolio sale to Boehringer-Ingelheim. His current project defining immuno-autonomics focusses on how autonomic nervous system (ANS) analysis with cloud-based, next-generation heart rate variability (HRV) enables substantially improved treatment remission rates in autoimmune disease, cancer and wherever stress impacts healthcare.